论文部分内容阅读
缺血性脑血管疾病治疗新药——“尼卡的平”是日本山之内制药公司中心研究实验室从一系列二氢吡啶衍化物中筛选出来的新型二氢吡啶类钙通道阻滞剂,通用名称NiCardipine,代号YC—93; 湖北省医药工业研究所于1979年开始研制,在国内首先合成本品;几年来先后在武汉、江西、云南、上海、四川、河南、吉林等地开展临床试验。观察健康受试者6例,脑血栓形成243例,其他缺血性脑血管疾病24例,共267例(不含对照组)。研究结果表明:临床观
Ischemic cerebrovascular disease treatment of new drugs - “Nika’s Ping” is Japan’s Yamanashi pharmaceutical company center research laboratory from a series of dihydropyridine derivatives selected from the new dihydropyridine calcium channel blockers, common name NiCardipine, code YC-93; Hubei Institute of Pharmaceutical Industry began to develop in 1979, the first synthesis of this product in China; in recent years in Wuhan, Jiangxi, Yunnan, Shanghai, Sichuan, Henan, Jilin and other places to carry out clinical trials. 6 healthy subjects, 243 cerebral thrombosis and 24 other ischemic cerebrovascular diseases were observed, totally 267 (without control group). The results show that: clinical concept